TFG Advisers’s Amphastar Pharmaceuticals AMPH Stock Holding History

TFG Advisers’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-250	Closed	-$4K	–	155
2019 Q4	$4K	Buy	+250	New	+$4.8K	﹤0.01%	432

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

TFG Advisers's AMPH Position: Q1 2020 in Review

TFG Advisers sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2020, closing a stake of 250 shares — an estimated $4K sold.

TFG Advisers first reported a position in AMPH in Q4 2019 and held it in 1 quarter. The position peaked at $4K in Q4 2019. 111 funds tracked by Wall St. Rank hold AMPH as of Q1 2020.

TFG Advisers reported no remaining Amphastar Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
TFG Advisers sold 250 Amphastar Pharmaceuticals shares in Q1 2020, an estimated $4K.
TFG Advisers first reported a position in Amphastar Pharmaceuticals in Q4 2019 and held it in 1 quarter.
TFG Advisers's Amphastar Pharmaceuticals position peaked at $4K in Q4 2019.
111 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2020.

Based on TFG Advisers's 13F filing for Q1 2020, filed 24 Apr 2020.